Therefore, the current efforts in anti-COVID-19 drug design targeting inflammasomes have shifted towards inhibitors of NLRP3 (DFV890, or dapansutrile, clinical trials NCT04382053) or gasdermin D (disulfiram [185], or dimethyl fumarate [186]), the latter of which is activated downstream of all inflammasome sensors. The gene discussed is NLRP3; the disease is COVID-19.